US5612197A - Process for producing recombinant human serum albumin - Google Patents
Process for producing recombinant human serum albumin Download PDFInfo
- Publication number
- US5612197A US5612197A US08/442,756 US44275695A US5612197A US 5612197 A US5612197 A US 5612197A US 44275695 A US44275695 A US 44275695A US 5612197 A US5612197 A US 5612197A
- Authority
- US
- United States
- Prior art keywords
- serum albumin
- human serum
- amino acid
- medium
- recombinant human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
Definitions
- This invention relates to the improvement of a process for producing recombinant human serum albumin (to be referred to as "HSA" hereinafter) by culturing a host transformed by means of gene manipulation techniques.
- HSA human serum albumin
- HSA is a main component of plasma proteins and is used in pharmaceutical preparations for the treatment of massive hemorrhage, shock, burn injury, hypoproteinemia, fetal erythroblastosis and the like.
- HSA is produced mainly as a product from fractions of collected blood.
- a production process is economically disadvantageous, and the supply of blood is sporadic.
- blood itself is also problematic in that it often contains undesirable substances such as hepatitis virus.
- An object of the present invention is to increase productivity of recombinant HSA in a process for the production thereof by means of gene engineering techniques, particularly to provide a large scale HSA production process which is effected by simple changes in the culture conditions of an HSA-producing host.
- productivity of HSA can be increased when an HSA-producing host, prepared by gene manipulation techniques, is cultured in an amino acid-containing medium.
- the present invention relates to a process for producing recombinant HSA which comprises culturing an HSA-producing host, prepared by gene manipulation techniques, in an amino acid-containing medium. More particularly, the present invention relates to a process for producing recombinant HSA, comprising:
- alanine to be referred to as "
- the culture medium contains at least one amino acid selected from the group consisting of Ala, Asp, Glu, His, Ser, Phe, Trp and Val.
- the culture medium contains at least one amino acid selected from the group consisting of Ala, Asp, His, Ser, Trp and Val.
- the culture medium contains at least one amino acid selected from the group consisting of Ala, Arg, His, Phe, Ser, Trp and Val.
- the culture medium contains His.
- the culture medium contains the amino acid(s) as described in the media above in an amount of from 0.08 to 20 w/v %.
- the HSA-producing host may be a yeast strain.
- the HSA-producing host to be used in the present invention is not particularly limited, provided that it is a cellular host prepared via gene manipulation techniques. Any of the hosts disclosed in published reports, and those which will be developed in the future may be used. Illustrative examples of such hosts include microorganisms (Escherichia coli, a yeast strain, Bacillus subtilis and the like), as well as animal cells, which have been made into HSA-producing cells by gene manipulation techniques.
- a strain of yeast especially belonging to the genus Saccharomyces, such as Saccharomyces cerevisiae, the genus Pichia, such as Pichia pastoris, the genus Kluyveromyces, such as Kluyveromyces lactis or the genus Hansenula, such as Hansenula polymorpha.
- Saccharomyces such as Saccharomyces cerevisiae
- Pichia pastoris the genus Kluyveromyces, such as Kluyveromyces lactis
- Hansenula polymorpha such as Hansenula polymorpha.
- An auxotrophic strain or an antibiotic sensitive strain may also be used.
- G418 sensitive strains such as Saccharomyces cerevisiae AH22 (a, his 4, leu 2, can 1), Pichia pastoris GTS115 (his 4) and Kluyveromyces lactis MW98-8c ( ⁇ , uraA, arg, lysK + , pKD1 0 ). It is preferable to use Pichia pastoris, particularly Pichia pastoris GTS115.
- Preparation of HSA-producing host production of HSA by its culturing and isolation and recovery of HSA from the cultured broth are all carried out in accordance with known methods which may be modified slightly.
- preparation of an HSA-producing host may be effected using a process in which a natural human serum albumin gene is used (JP-A-58-56684 corresponding to EP-A-73646, JP-A-58-90515 corresponding to EP-A-79739 and JP-A-58-150517 corresponding to EP-A-91527), a process in which a modified human serum albumin gene is used (JP-A-62-29985 and JP-A-1-98486 corresponding to EP-A-206733), a process in which a synthetic signal sequence is used (JP-A-1-240191 corresponding to EP-A-329127), a process in which a serum albumin signal sequence is used (JP-A-2-167095 corresponding to EP-A-319641),
- subtilis JP-A-62-215393 corresponding to EP-A-229712
- a process in which HSA is expressed in yeast JP-A-60-41487 corresponding to EP-A-123544, JP-A-63-39576 corresponding to EP-A-248657 and JP-A-63-74493 corresponding to EP-A-251744
- a process in which HSA is expressed in Pichia JP-A-2-104290 corresponding to EP-A-344459.
- a transformant of an appropriate host preferably a Pichia yeast, illustratively a strain GTS115 (NRRL deposition No. Y-15851), is obtained in the usual manner by introducing a plasmid, containing a transcription unit by which HSA is expressed under the control of the AOX 1 promoter, into the AOX 1 gene region of the host (cf. JP-A 2-104290).
- This transformant hardly grows in a medium containing methanol.
- this transformant is cultured in a methanol-containing medium to generate mutation, and a strain capable of growing in the medium is isolated.
- Methanol concentration in the medium may range, for example, from 0.0001 to 5%.
- the medium may be either synthetic or natural.
- the culturing may be carried out, for example, at a temperature of from 15° to 40° C. for approximately from 1 to 1,000 hours.
- Culturing of the HSA-producing host may be effected by each of the methods disclosed in the above patents, by a method in which producer cells and the product are obtained in high concentrations by a fed-batch culture which method is carried out by gradually supplying a high concentration solution of glucose in appropriate small amounts to avoid high concentration substrate inhibition against the producer cells (JP-A-3-83595), by a method in which the HSA productivity is improved by the addition of fatty acids to the culture medium (JP-A-4-293495 corresponding to EP-A-504823 and U.S. Pat. No.
- the medium to be used in the production process of the present invention is an amino acid-containing medium, especially a medium which contains at least 1 amino acid selected from neutral amino acids such as glycine (to be referred to as “Gly” hereinafter), Ala, Ser, Val, leucine (to be referred to as “Leu” hereinafter), Ile, Cys, Phe, Trp or Proline (to be referred to as “Pro” hereinafter), acidic amino acids such as Asp or Glu and basic amino acids such as Arg or His.
- neutral amino acids such as glycine (to be referred to as "Gly” hereinafter), Ala, Ser, Val, leucine (to be referred to as “Leu” hereinafter), Ile, Cys, Phe, Trp or Proline (to be referred to as “Pro” hereinafter)
- acidic amino acids such as Asp or Glu
- basic amino acids such as Arg or His.
- An example of a medium capable of markedly increasing HSA productivity when used in the culturing of an HSA-producing host is a medium which contains at least 1 amino acid selected from the group consisting of Ala, Arg, Asp, Glu, Gly, His, Phe, Ser, Trp, Cys, Ile and Val, preferably a medium which contains at least 1 amino acid selected from the group consisting of Ala, Asp, Glu, His, Phe, Ser, Trp and Val, more preferably a medium which contains at least 1 amino acid selected from the group consisting of Ala, Asp, His, Ser, Trp and Val.
- a medium which contains at least 1 amino acid selected from the group consisting of Ala, Arg, His, Ser, Trp, Phe, and Val is effective in producing HSA in a large quantity without allowing an HSA-producing host itself to grow when used in the culturing of the host.
- Production of a large quantity of HSA by not allowing the host cells themselves to grow significantly is advantageous especially in the case of an expression system in which HSA is allowed to secrete into culture supernatant, because the ratio of culture supernatant to the amount of culture broth (medium) becomes large so that HSA can be recovered in a higher yield.
- a medium which contains His is particularly preferred as the medium to be used in the present invention.
- This medium is especially good for improving productivity of HSA, because it can considerably increase production yield of HSA independent of the growth of the HSA-producing host itself.
- the medium to be used in the present invention may contain the above-described amino acid alone or as a mixture of two or more amino acids.
- the amino acid content of the medium may range, for example, from about 0.08 to 20 w/v %, preferably from about 0.1 to 1 w/v %.
- components of the medium to be used in the present invention are not particularly limited, provided that the medium contains at least one of the above-described amino acids.
- examples of other components are those which are contained in known culture media generally used in this field.
- various sugars are used as carbon sources, urea, ammonium salts, nitrates and the like are used as nitrogen sources and various vitamins, nucleotides and the like are used as trace nutrients, as well as inorganic salts such as of Mg, Ca, Fe, Na, K, Mn, Co, Cu and the like.
- Illustrative examples of the useful medium include YNB liquid medium (0.7% Yeast Nitrogen Base without amino acids (manufactured by Difco) and 2% glucose), MeOH-ammonium acetate medium (composition: cf. Examples), YPD liquid medium (1% Yeast Extract (Difco), 2% Bacto-peptone (Difco) and 2% glucose) and the like.
- a methanol-containing medium may be used. In that case, the methanol concentration may range approximately from 0.01 to 5%.
- the medium to be used in the present invention can be prepared easily, by adding the above-described amino acid(s) to any known medium.
- the pH of the medium may be neutral, slightly basic or slightly acidic.
- the medium may have a pH value of from about 5.7 to 6.5.
- Culture conditions may be selected in the usual way.
- the culture temperature may range, for example, generally from about 15° to 43° C. It may range from about 20° to 37° C. when the host is a bacterium. It may range from about 20° to 30° C. when the host is a yeast. Particularly, the yeast host may be cultured at a temperature of generally from 21° to 29° C., preferably 21° to 28° C., more preferably 23° to 28° C., most preferably 25° to 27° C. The culture period is approximately from 1 to 1,000 hours.
- the seed culturing may be carried out for, for example, about 10 to 100 hours preferably at about 30° C. in the case of yeast strains or about 37° C. in the case of bacterial strains.
- the above-described amino acid(s) may also be used in the seed culturing.
- HSA is collected from the culture supernatant (filtrate) or cells by isolation and purification means commonly known.
- isolation and purification means commonly known.
- HSA is purified by subjecting a culture supernatant (filtrate) to ultrafiltration, heat treatment, acid treatment and ultrafiltration, in that order, and then to respective treatments with cation exchanger, hydrophobic chromatography and anion exchanger (JP-A-5-317079 corresponding to EP-A-570916) and a method in which HSA is decolorized by chelate resin treatment (JP-A-5-328991 corresponding to EP-A-570916).
- a strain of Pichia pastoris, PC4130 has been obtained in accordance with the method disclosed in JP-A-2-104290, by substituting the AOX 1 gene region of P. pastoris GTS115 (his 4) with a NotI-digested fragment of plasmid pPGP1 which contains a transcription unit by which HSA is expressed under the control of the AOX 1 promoter. Because of the absence of the AOX 1 gene, this strain has a reduced ability to grow on a medium which contains methanol as the carbon source (methanol assimilation negative strain; to be referred to as "Mut - strain" hereinafter).
- the strain PC4130 was inoculated into 3 ml of YPD medium (1% yeast extract, 2% Bacto Peptone and 2% glucose). After 24 hours of culturing, the cells were inoculated into 50 ml of YPD medium so that the cell density was adjusted to initial turbidity with an OD 540 of 0.1. After 3 days of culturing at 30° C., the resulting cells again were inoculated into 50 ml of YPD medium at an initial cell turbidity of 0.1 at OD 540 . Thereafter, subculturing was repeated every 3 days in the same manner. After each subculturing, cells were diluted with sterile water and poured onto a 2% MeOH-YNBw/oa.a.
- An HSA expression plasmid pMM042 was constructed using an AOX 2 promoter (a mutant of the natural AOX 2 promoter (YEAST, 5, 167-177, 1988; Mol. Cell. Biol., 4, 1316-1323, 1989), in which the 255th base upstream from the initiation codon of said promoter is changed from T to C) isolated from the above-described strain GCP101.
- the thus constructed plasmid was introduced into Pichia pastoris GTS115 to obtain a transformant UHG42-3 (JP-A-4-299984 or EP-A-506040).
- YPD medium (2% Bacto-peptone, 1% yeast extract and 2% glucose) was used for the seed culture.
- a MeOH-ammonium acetate medium shown in Table 1 was used in the main culture.
- a 1 ml portion of the strain contained in a freeze-dried stock vial was inoculated into a 300-ml baffled Erlenmeyer flask containing 50 ml of YPD medium and cultured at 30° C. for 24 hours with shaking.
- a 1 ml portion of the seed culture medium was inoculated into a 300-ml baffled Erlenmeyer flask containing 50 ml of the MeOH-ammonium acetate medium which had been supplemented with each amino acid to give a final concentration of 0.1% and adjusted to pH 6.0, and cultured at 30° C. for 89 hours with shaking.
- Example 1 (3) ii the culture broth was sampled at optional intervals, each of the thus collected samples was diluted with distilled water to give the OD 540 value of 0.3 or less at the time of measurement, and then absorbance of the diluted sample at 540 nm was measured using a spectrophotometer (UV 200, manufactured by Shimadzu Corp.).
- a 350 /A 280 values were calculated using the results of the HPLC gel filtration analysis carried out for the evaluation of HSA productivity, and these values were used for the evaluation of coloring degree of HSA produced by the process of the present invention.
- yield of HSA can be increased significantly when an HSA-producing host is cultured in a medium which contains an amino acid, especially Ala, Asp, Glu, His, Phe, Trp, Val or Ser.
- an amino acid-free culture system it was found that the HSA yield-increasing effect of a medium which contains Ala, His, Phe, Trp, Val or Ser or a medium which contains Arg or Cys was not due to an increase in the cell yield.
- yield of HSA by an HSA-producing host prepared by gene manipulation techniques can be increased by employing a process which can be carried out easily with a relatively low cost by simply changing culture conditions.
- the HSA production yield can be increased 1.5 to 5 times in comparison with the case of culturing with no supplement of amino acids, when cultured using a medium which contains at least one amino acid selected from Ala, Asp, Glu, His, Phe, Trp, Val and Ser.
- the HSA production yield can be increased 1.3 to 5 times independent of the cell growth.
- Such an effect is particularly significant in a His-containing medium. Also, the HSA productivity-increasing effect can be obtained even with a relatively small amino acid content of 0.08 to 1 w/v %. In addition, some of the above-described amino acids can reduce coloring of the produced HSA.
- the HSA production process of the present invention can be regarded as practically useful.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
TABLE 1 ______________________________________ Composition of MeOH-ammonium acetate medium Concentration Component (mg/l) ______________________________________ Methanol 40 ml Glycerol 1,000 CH.sub.3 COONH.sub.4 5,000 KH.sub.2 PO.sub.4 10,000 CaCl.sub.2 2H.sub.2 O 100 KCl 2,000 NaCl 100 MgSO.sub.4 7H.sub.2 O 2,000 ZnSO.sub.4 7H.sub.2 O 100 CuSO.sub.4 5H.sub.2 O 5 FeCl.sub.3 6H.sub.2 O 100 Biotin 0.1 Vitamin B.sub.1 10 Vitamin B.sub.6 1 Sodium pantothenate 10 Inositol 50 ______________________________________
TABLE 2 ______________________________________ Amino acid and Cell Yield Coloring other components Yield (%) (%) degree (%) ______________________________________ Control 100 100 100 Yeast extract 157 118 127 Peptone 122 120 122 Gly 127 123 145 Ala 220 99 112 Asp 258 111 135 Arg 132 98 125 Glu 173 109 145 His 410 76 96 Ile 144 105 118 Lys 42 83 104 Met 28 24 124 ______________________________________
TABLE 3 ______________________________________ Amino acid and Cell yield Coloring other components Yield (%) (%) degree (%) ______________________________________ Control 100 100 100 His 439 65 72 Lys 21 44 97 Ala 146 103 109 Asp 221 107 131 Trp 238 91 215 Val 235 87 102 Leu 117 102 111 Ser 200 91 105 Thr 105 103 137 Asn 119 121 139 Gln 78 113 105 Pro 114 115 135 Ca pantothenate 72 106 120 ______________________________________
TABLE 4 ______________________________________ Cell yield Coloring Amino acid Yield (%) (%) degree (%) ______________________________________ Control 100% 100% 100% Phe 165 89 112 Cys 134 98 161 ______________________________________
TABLE 5 ______________________________________ Amino Concentration Yield Cell Yield Coloring acid % (w/v) (%) (%) degree (%) ______________________________________ Control 100 100 100 His 0.1 326 82 112 His 0.2 214 67 88 His 0.3 188 86 71 His 0.4 185 89 71 His 0.6 159 71 76 His 1.0 133 85 71 ______________________________________
Claims (17)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6-103994 | 1994-05-18 | ||
JP6103994A JPH07308199A (en) | 1994-05-18 | 1994-05-18 | Production of human serum albumin |
Publications (1)
Publication Number | Publication Date |
---|---|
US5612197A true US5612197A (en) | 1997-03-18 |
Family
ID=14368857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/442,756 Expired - Fee Related US5612197A (en) | 1994-05-18 | 1995-05-17 | Process for producing recombinant human serum albumin |
Country Status (6)
Country | Link |
---|---|
US (1) | US5612197A (en) |
EP (1) | EP0683233A3 (en) |
JP (1) | JPH07308199A (en) |
KR (1) | KR100404273B1 (en) |
CA (1) | CA2149579A1 (en) |
TW (1) | TW403786B (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002005645A1 (en) * | 2000-07-14 | 2002-01-24 | New Century Pharmaceuticals | Modified serum albumin with reduced affinity for nickel and copper |
WO2008030558A2 (en) | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and their uses |
CN100402649C (en) * | 2000-05-10 | 2008-07-16 | 阿斯比奥制药株式会社 | Method of inhibiting the formation of by-product in the production of genetically modified polypeptide |
EP2228439A1 (en) | 2000-06-09 | 2010-09-15 | Vitrolife AB | Mammalian gamete and embryo culture media supplement and method of using same |
EP1398038B2 (en) † | 2000-02-08 | 2011-01-26 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions |
US20110098477A1 (en) * | 2005-06-28 | 2011-04-28 | Chugai Seiyaku Kabushiki Kaisha | Method Of Producing Compound Having Anti-Hcv Activity |
US7993877B2 (en) | 1999-01-30 | 2011-08-09 | Novozymes Biopharma Dk A/S | Process for the purification of recombinant albumin |
US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000043035A1 (en) | 1999-01-19 | 2000-07-27 | Nissho Corporation | Amino acid-containing albumin preparations |
AU2005318697A1 (en) * | 2004-12-22 | 2006-06-29 | Novozymes A/S | Recombinant production of serum albumin |
CN102127164B (en) | 2010-12-20 | 2013-01-30 | 武汉禾元生物科技有限公司 | Method for extracting recombinant human serum albumin from rice seeds |
CN102532254B (en) | 2010-12-24 | 2015-06-24 | 武汉禾元生物科技股份有限公司 | Method for separating and purifying recombinant human serum albumin (rHSA) from rice seeds |
WO2013006675A1 (en) | 2011-07-05 | 2013-01-10 | Novozymes Biopharma Uk Limited | Albumin formulation and use |
CN103880947B (en) | 2012-12-21 | 2016-01-13 | 武汉禾元生物科技股份有限公司 | A kind of chromatography method of separating and purifying high-purity recombination human serum albumin |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5294699A (en) * | 1990-06-25 | 1994-03-15 | The Green Cross Corporation | Inhibition of coloration of human serum albumin |
US5330901A (en) * | 1991-04-26 | 1994-07-19 | Research Corporation Technologies, Inc. | Expression of human serum albumin in Pichia pastoris |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR964053A (en) * | 1950-08-04 | |||
GB2105003B (en) | 1981-08-27 | 1983-10-12 | British Gas Corp | Valve assembly |
IL66614A (en) | 1981-08-28 | 1985-09-29 | Genentech Inc | Method of constructing a dna sequence encoding a polypeptide,microbial production of human serum albumin,and pharmaceutical compositions comprising it |
EP0079739A3 (en) | 1981-11-12 | 1984-08-08 | The Upjohn Company | Albumin-based nucleotides, their replication and use, and plasmids for use therein |
EP0091527A3 (en) | 1981-12-14 | 1984-07-25 | The President And Fellows Of Harvard College | Dna sequences, recombinant dna molecules and processes for producing human serum albumin-like polypeptides |
JPS6041487A (en) | 1983-04-25 | 1985-03-05 | ジエネンテツク・インコ−ポレイテツド | Use of alpha factor arrangement in yeast development system |
NZ207926A (en) | 1983-04-25 | 1988-04-29 | Genentech Inc | Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast |
EP0206733A1 (en) | 1985-06-17 | 1986-12-30 | Genex Corporation | Cloned human serum albumin gene |
DK13087A (en) | 1986-01-13 | 1987-07-14 | Genex Corp | REVENUE FOR THE MANUFACTURE OF HUMAN SERUM ALBUMIN IN BACILLUS |
GB8613388D0 (en) | 1986-06-03 | 1986-07-09 | Delta Biotechnology Ltd | Induction of galactose regulated gene expression in yeast |
US4723944A (en) | 1986-06-05 | 1988-02-09 | Jensen Ole R | Fluid collection receptacle with improved non-return valve |
JPH0198486A (en) | 1986-06-17 | 1989-04-17 | Genex Corp | Cloned prepro-human serum albumin gene and human serum albumin gene, plasmid containing these genes,microorganism transformed by plasmid,and production of prepro-human serum albumin by using said microorganism |
GB8615701D0 (en) | 1986-06-27 | 1986-08-06 | Delta Biotechnology Ltd | Stable gene integration vector |
SE459586B (en) * | 1987-09-14 | 1989-07-17 | Mta Szegedi Biolog Koezponti | THE STRUCTURES CODING FOR AUTHENTIC HUMAN SERUM ALBUMIN AND PROCEDURES FOR ITS PREPARATION |
JP2791418B2 (en) | 1987-12-02 | 1998-08-27 | 株式会社ミドリ十字 | Method for producing heterologous protein, recombinant DNA, transformant |
JPH01240191A (en) | 1988-02-16 | 1989-09-25 | Green Cross Corp:The | Novel signal peptide functioning by yeast and secretory manifestation of foreign protein using same |
IL89992A0 (en) | 1988-04-25 | 1989-12-15 | Phillips Petroleum Co | Expression of human serum albumin in methylotrophic yeasts |
JPH0669365B2 (en) | 1989-05-22 | 1994-09-07 | 株式会社ミドリ十字 | Albumin gene-containing plasmid, transformant, method for producing transformant, method for producing albumin |
CA2017176A1 (en) | 1989-05-22 | 1990-11-22 | Yoshitomi Pharmaceutical Industries Ltd. | Albumin gene-containing plasmid, transformant carrying same, production of such transformant and production of albumin |
JP2855130B2 (en) | 1989-07-19 | 1999-02-10 | 吉富製薬株式会社 | Fusion yeast for expressing heterologous protein, method for producing the same, and method for producing heterologous protein |
JPH0877B2 (en) | 1989-08-25 | 1996-01-10 | 株式会社ミドリ十字 | Method for producing human serum albumin |
JPH0671432B2 (en) | 1991-03-20 | 1994-09-14 | 株式会社ミドリ十字 | Method for producing human serum albumin |
JPH07106153B2 (en) | 1991-03-27 | 1995-11-15 | 株式会社ミドリ十字 | Method for producing plasmid carrying transformant AOX2 promoter, transformant and heterologous protein |
CA2063890C (en) | 1991-03-27 | 2007-03-13 | Masami Miura | Mutant aox2 promoter, microorganism carrying same, method of preparation thereof and production of heterologous protein using such microorganism |
JPH07102147B2 (en) | 1992-03-16 | 1995-11-08 | 株式会社ミドリ十字 | Method for suppressing coloration of human serum albumin |
JPH0675513B2 (en) | 1992-05-28 | 1994-09-28 | 株式会社ミドリ十字 | Method for decolorizing human serum albumin |
US5440018A (en) | 1992-05-20 | 1995-08-08 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
JPH07102148B2 (en) | 1992-05-20 | 1995-11-08 | 株式会社ミドリ十字 | Method for producing human serum albumin obtained by genetic engineering, and human serum albumin-containing composition obtained thereby |
-
1994
- 1994-05-18 JP JP6103994A patent/JPH07308199A/en active Pending
-
1995
- 1995-05-17 US US08/442,756 patent/US5612197A/en not_active Expired - Fee Related
- 1995-05-17 CA CA002149579A patent/CA2149579A1/en not_active Abandoned
- 1995-05-18 KR KR1019950012350A patent/KR100404273B1/en not_active IP Right Cessation
- 1995-05-18 EP EP95107621A patent/EP0683233A3/en not_active Withdrawn
- 1995-07-27 TW TW084107771A patent/TW403786B/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5294699A (en) * | 1990-06-25 | 1994-03-15 | The Green Cross Corporation | Inhibition of coloration of human serum albumin |
US5330901A (en) * | 1991-04-26 | 1994-07-19 | Research Corporation Technologies, Inc. | Expression of human serum albumin in Pichia pastoris |
Non-Patent Citations (4)
Title |
---|
Cook (ed.) "The chemistry and biology of yeasts", Academic Press, New York, N.Y. p. 171 (1958). |
Cook (ed.) The chemistry and biology of yeasts , Academic Press, New York, N.Y. p. 171 (1958). * |
Further Studies on the role of phenylalanine in gramicidin S biosynthesis by Bacillus brevis, J H. David Wu et al., Journal of Biotechnology, pp. 81 94. * |
Further Studies on the role of phenylalanine in gramicidin S biosynthesis by Bacillus brevis, J-H. David Wu et al., Journal of Biotechnology, pp. 81-94. |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7993877B2 (en) | 1999-01-30 | 2011-08-09 | Novozymes Biopharma Dk A/S | Process for the purification of recombinant albumin |
US9029102B2 (en) | 1999-01-30 | 2015-05-12 | Novozymes Biopharma Dk A/S | Process for the purification of recombinant albumin |
US9555344B2 (en) | 1999-01-30 | 2017-01-31 | Albumedix A/S | Process for the purification of recombinant albumin |
EP1398038B2 (en) † | 2000-02-08 | 2011-01-26 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions |
CN100402649C (en) * | 2000-05-10 | 2008-07-16 | 阿斯比奥制药株式会社 | Method of inhibiting the formation of by-product in the production of genetically modified polypeptide |
EP2228439A1 (en) | 2000-06-09 | 2010-09-15 | Vitrolife AB | Mammalian gamete and embryo culture media supplement and method of using same |
WO2002005645A1 (en) * | 2000-07-14 | 2002-01-24 | New Century Pharmaceuticals | Modified serum albumin with reduced affinity for nickel and copper |
US6787636B1 (en) | 2000-07-14 | 2004-09-07 | New Century Pharmaceuticals, Inc. | Modified serum albumin with reduced affinity for nickel and copper |
US20110098477A1 (en) * | 2005-06-28 | 2011-04-28 | Chugai Seiyaku Kabushiki Kaisha | Method Of Producing Compound Having Anti-Hcv Activity |
WO2008030558A2 (en) | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and their uses |
US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
Also Published As
Publication number | Publication date |
---|---|
TW403786B (en) | 2000-09-01 |
EP0683233A3 (en) | 2000-05-03 |
KR100404273B1 (en) | 2004-03-02 |
KR950032617A (en) | 1995-12-22 |
CA2149579A1 (en) | 1995-11-19 |
JPH07308199A (en) | 1995-11-28 |
EP0683233A2 (en) | 1995-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5612197A (en) | Process for producing recombinant human serum albumin | |
US5965386A (en) | Yeast strains and modified albumins | |
Kamada et al. | The purification of the extracellular acid protease of Rhodotorula glutinis K-24 and its general properties | |
US5334512A (en) | Fatty acid supplemented medium for recombinant production of human serum albumin by yeast | |
US5656729A (en) | Method for highly purifying human serum albumin | |
CN117126754A (en) | Recombinant type I collagen pichia pastoris engineering bacteria, construction method and application thereof | |
JPH05317079A (en) | Production of human serum albumin obtained by genetic engineering and composition containing human serum albumin produced thereby | |
US5369020A (en) | Method for suppressing coloring of human serum albumin | |
CA2136564C (en) | Process for producing human serum albumin | |
RU2141531C1 (en) | Method of recombinant human insulin preparing | |
JP2869417B2 (en) | Human serum albumin obtained by genetic manipulation | |
AU746670B2 (en) | Process for producing foreign proteins | |
JP3772355B2 (en) | Method for producing human serum albumin | |
JPH09176195A (en) | High-purity human serum albumin-containing composition obtained by human serum albumin derived from genetic engineering | |
Van Thinh et al. | Amino acid composition of autotrophic and heterotrophic cultures of the Emerson strain, of Chlorella | |
JP2005312463A (en) | Method for producing human serum albumin | |
JPH06245789A (en) | Human serum albumin and its production | |
EP0550626A1 (en) | Method of improving the yield of heterologous proteins produced by streptomyces lividans | |
JPH1014564A (en) | Production of protein | |
JP2608450B2 (en) | New koji mold and its use | |
JPH11191A (en) | Human serum albumin obtained by gene manipulation | |
JPH09322764A (en) | Suppression of human serum albumin decomposition | |
JPH06245788A (en) | Human serum albumin and its production | |
JPH0675513B2 (en) | Method for decolorizing human serum albumin | |
JPS5816880B2 (en) | Method for producing L-leupeptin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GREEN CROSS CORPORATION, THE, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:OHDA, TOYOO;OHTANI, WATARU;OHYA, TOMOSHI;AND OTHERS;REEL/FRAME:007569/0721 Effective date: 19950616 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
AS | Assignment |
Owner name: YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD., JAPAN Free format text: CHANGE OF NAME;ASSIGNOR:GREEN CROSS CORPORATION, THE;REEL/FRAME:009980/0934 Effective date: 19990312 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: WELFIDE CORPORATION, JAPAN Free format text: CHANGE OF NAME;ASSIGNOR:YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.;REEL/FRAME:012066/0224 Effective date: 20010127 |
|
AS | Assignment |
Owner name: MITSUBISHI PHARMA CORPORATION, JAPAN Free format text: MERGER;ASSIGNOR:WELFIDE CORPORATION;REEL/FRAME:012698/0582 Effective date: 20011001 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20090318 |